I-Tirzepatide umuthi wenoveli omelela impumelelo enkulu ekwelapheni isifo sikashukela sohlobo 2 nokukhuluphala. I-agonist yokuqala ekabili ye-insulinotropic polypeptide (GIP) encike ku-glucose kanye ne-glucagon-like peptide-1 (GLP-1) receptors. Le ndlela yokusebenza eyingqayizivele iyenza ihluke ekwelashweni okukhona futhi inika amandla imiphumela eqinile kukho kokubili ukulawula ushukela wegazi nokwehliswa kwesisindo.
Ngokuvula ama-GIP nama-GLP-1 receptors, i-Tirzepatide ithuthukisa ukukhiqizwa kwe-insulin nokuzwela, yehlisa ukukhiqizwa kwe-glucagon, yehlisa ukuphuma kwesisu, futhi yehlise isifiso sokudla.
Ilawulwa njengomjovo ongaphansi kwesikhumba kanye ngeviki, i-Tirzepatide ibonise ukusebenza kahle okuphawulekayo ezivivinyweni zomtholampilo. Ithuthukisa kakhulu ukulawulwa kwe-glycemic futhi yehlise isisindo somzimba, imvamisa idlula ukusebenza kwemithi etholakalayo njengamanje. Ukwengeza, izinzuzo ezingaba khona zenhliziyo ziye zabonwa.
Imiphumela engemihle evame kakhulu ukuthunjwa kwamathumbu, okuhlanganisa isicanucanu, isifo sohudo, nokuhlanza, okuvamise ukuba maphakathi kuya kokulinganisela ngokuqina futhi kuvame ukuncipha ngokuhamba kwesikhathi.
Sekukonke, ukuthuthukiswa kwe-Tirzepatide kuphawula umngcele omusha ekwelapheni izifo ze-metabolic, okunikeza ithuluzi elinamandla lokulawula kokubili isifo sikashukela nokukhuluphala.
Isikhathi sokuthumela: Sep-01-2025